About
About Cantargia AB (publ)
Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an monoclonal antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in phase 1 clinical trial for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops CANxx, an IL1RAP-based antibody platform. The company has collaboration agreements with Otsuka Pharmaceutical Co., Ltd for the clinical IL1RAP targeting antibody CAN10 as well as the preclinical antibody 3G5; and BioWa Inc., granted a nonexclusive license to use the technology platform POTELLIGENT® for the manufacture of the drug candidate nadunolimab. Cantargia AB (publ) was incorporated in 2009 and is based in Lund, Sweden.
Visit company website
5 years, 5 months ago
Cantargia AB (publ) is currently in a long term downtrend where the price is trading 46.9% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Cantargia AB (publ)'s total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 9.0% to $-40M since the same quarter in the previous year.
Finally, its free cash flow fell by 18.4% to $-45M since the same quarter in the previous year.
Based on the above factors, Cantargia AB (publ) gets an overall score of 1/5.